A Single-Dose, Open-Label, Randomized, Replicate Crossover Study in Healthy Adult Subjects to Assess the Bioequivalence of an Ibrutinib 140-mg Tablet Compared to the IMBRUVICA 140-mg Capsule
Phase of Trial: Phase I
Latest Information Update: 14 Mar 2017
At a glance
- Drugs Ibrutinib (Primary)
- Indications Leukaemia; Lymphoma; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Waldenstrom's macroglobulinaemia
- Focus Pharmacokinetics
- Sponsors Janssen Research & Development
- 08 Mar 2017 Status changed from recruiting to completed.
- 23 Nov 2016 Planned End Date changed from 1 Oct 2016 to 1 Nov 2016.
- 23 Nov 2016 Planned primary completion date changed from 1 Oct 2016 to 1 Nov 2016.